An open-label, phased-increasing dose, Phase 1/2a clinical trial to evaluate the safety and efficacy of allogeneic placenta-derived mesenchymal stem cell therapy (PLARTISTEM®) in patients with osteoarthritis
Latest Information Update: 02 Dec 2020
Price :
$35 *
At a glance
- Drugs Allogeneic placenta derived mesenchymal stem cell therapy Medicrinia (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Medicrinia
- 02 Dec 2020 New trial record